Public Employees Retirement System of Ohio Buys Shares of 10,939 Penumbra, Inc. $PEN

Key Points

• Public Employees Retirement System of Ohio acquired 10,939 Penumbra shares worth approximately $3.45 million during the second quarter. Institutional investors and hedge funds collectively own 88.88% of the company.
• Penumbra reported quarterly revenue of $390.05 million, up 14.9% year over year and slightly above expectations, but earnings per share of $0.88 missed consensus estimates of $1.16.
• Analysts maintain a consensus “Hold” rating, with a consensus price target of $367.07, compared with the stock’s reported price of $322.28.

Public Employees Retirement System of Ohio acquired a new stake in Penumbra, Inc. (NYSE:PEN - Free Report) during the second quarter, according to its most recent filing with the SEC. The firm acquired 10,939 shares of the company's stock, valued at approximately $3,454,000.

Several other institutional investors also recently bought and sold shares of the company. PenderFund Capital Management Ltd. acquired a new stake in shares of Penumbra in the 2nd quarter worth $369,000. Corient Private Wealth LP purchased a new stake in shares of Penumbra in the second quarter valued at about $514,000. Bank of America Corp DE acquired a new position in shares of Penumbra during the second quarter worth about $83,995,000. Sculptor Capital LP acquired a new position in shares of Penumbra during the second quarter worth about $17,998,000. Finally, Odyssean LLC raised its holdings in Penumbra by 112.2% during the second quarter. Odyssean LLC now owns 9,328 shares of the company's stock worth $2,945,000 after purchasing an additional 4,932 shares in the last quarter. 88.88% of the stock is owned by institutional investors and hedge funds.

Penumbra Stock Performance

Shares of NYSE PEN opened at $322.28 on Friday. The company has a 50-day simple moving average of $321.25 and a 200-day simple moving average of $326.29. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.75 and a quick ratio of 3.86. The company has a market cap of $12.69 billion, a PE ratio of 79.18, a price-to-earnings-growth ratio of 2.21 and a beta of 0.70. Penumbra, Inc. has a 12 month low of $221.26 and a 12 month high of $362.41.

Penumbra (NYSE:PEN - Get Free Report) last released its earnings results on Thursday, July 30th. The company reported $0.88 earnings per share for the quarter, missing the consensus estimate of $1.16 by ($0.28). The business had revenue of $390.05 million for the quarter, compared to analysts' expectations of $389.64 million. Penumbra had a return on equity of 10.50% and a net margin of 10.67%.The business's quarterly revenue was up 14.9% compared to the same quarter last year. During the same quarter last year, the company posted $0.86 earnings per share. On average, equities analysts anticipate that Penumbra, Inc. will post 4.96 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on PEN. Evercore restated an "outperform" rating and issued a $320.00 price objective on shares of Penumbra in a research report on Monday, July 6th. Wall Street Zen upgraded Penumbra to a "hold" rating in a research report on Saturday, May 9th. Royal Bank Of Canada reissued a "sector perform" rating and set a $374.00 target price on shares of Penumbra in a research note on Thursday, June 11th. Zacks Research raised Penumbra from a "strong sell" rating to a "hold" rating in a report on Monday, August 24th. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Penumbra in a research note on Friday, July 17th. Three investment analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $367.07.

Penumbra Profile

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra's technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra's portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.

Want to see what other hedge funds are holding PEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Penumbra, Inc. (NYSE:PEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source